This Drug Could Treat Psoriatic Arthritis and Ankylosing Spondylitis
12019 / Pixabay

This Drug Could Treat Psoriatic Arthritis and Ankylosing Spondylitis

According to a story from globenewswire.com, Galapagos NV and Gilead Sciences, Inc., recently announced that two clinical trials which were recently published in The Lancet demonstrated that the experimental treatment filgotinib could…

Continue Reading This Drug Could Treat Psoriatic Arthritis and Ankylosing Spondylitis
Should Medicine Stop Focusing on Individual Diseases and Start Treating Combinations of Conditions?
rawpixel / Pixabay

Should Medicine Stop Focusing on Individual Diseases and Start Treating Combinations of Conditions?

Multimorbidity, typically defined as having two or more long-term health conditions, has become a topic of increasing focus for healthcare providers. Many elderly people are affected by multimorbidity, with the…

Continue Reading Should Medicine Stop Focusing on Individual Diseases and Start Treating Combinations of Conditions?
Experimental Treatment for ITP Gets Orphan Drug Designation
mohamed_hassan / Pixabay

Experimental Treatment for ITP Gets Orphan Drug Designation

According to a story from financialbuzz.com, the biopharmaceutical company Principia Biopharma recently announced that its experimental medical product PRN1008 has received Orphan Drug designation from the US Food and Drug…

Continue Reading Experimental Treatment for ITP Gets Orphan Drug Designation
FDA Approves Investigational New Drug Application For an Experimental Treatment for Guillain-Barre Syndrome
RobinHiggins / Pixabay

FDA Approves Investigational New Drug Application For an Experimental Treatment for Guillain-Barre Syndrome

According to a story from BioSpace, the biotechnology company Cellenkos, Inc., recently announced that the US Food and Drug Administration (FDA) has given the company the go ahead to begin…

Continue Reading FDA Approves Investigational New Drug Application For an Experimental Treatment for Guillain-Barre Syndrome
Trial Results are Positive for a Potential Treatment for Contrast-Induced Nephropathy
jarmoluk / Pixabay

Trial Results are Positive for a Potential Treatment for Contrast-Induced Nephropathy

According to a story from markets.businessinsider.com, the drug development company Pharming Group N.V. recently announced results from a Phase II trial testing its medication RUCONEST. This drug was tested as…

Continue Reading Trial Results are Positive for a Potential Treatment for Contrast-Induced Nephropathy

EyeForPharma’s Annual Patient Summit USA

  • Post author:
  • Post category:

The 15th Annual Patient Summit USA At this conference, representatives from the medical field are invited to converge to learn what it truly means to put patients first. If you…

Continue Reading EyeForPharma’s Annual Patient Summit USA
Lifestyle Changes Can Make a Big Difference in Nonalcoholic Steatohepatitis (NASH)
Free-Photos / Pixabay

Lifestyle Changes Can Make a Big Difference in Nonalcoholic Steatohepatitis (NASH)

According to a story from Healio, Dr. Monica Konerman recently gave a presentation about the importance of lifestyle changes in treating nonalcoholic fatty liver disease and its rarer and more…

Continue Reading Lifestyle Changes Can Make a Big Difference in Nonalcoholic Steatohepatitis (NASH)
Families Hope That Provinces in Canada Will Cover Expensive Therapies for Rare Diseases
source: pixabay.com

Families Hope That Provinces in Canada Will Cover Expensive Therapies for Rare Diseases

British Columbia faces excruciating decisions about how and whether to cover drug treatment for rare diseases. One particular drug is Spinraza.  It is a drug that is a part of…

Continue Reading Families Hope That Provinces in Canada Will Cover Expensive Therapies for Rare Diseases